211 related articles for article (PubMed ID: 34496018)
1. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis.
Henriques A; Muñoz-González JI; Sánchez-Muñoz L; Matito A; Torres-Rivera L; Jara-Acevedo M; Caldas C; Mayado A; Pérez-Pons A; García-Montero AC; Álvarez-Twose I; Orfao A
Blood; 2022 Jan; 139(4):572-583. PubMed ID: 34496018
[TBL] [Abstract][Full Text] [Related]
2. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
3. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
6. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P; Álvarez-Twose I; Pérez-Pons A; Henriques A; Mayado A; García-Montero AC; Sánchez-Muñoz L; González-López O; Matito A; Caldas C; Jara-Acevedo M; Orfao A
Allergy; 2023 May; 78(5):1347-1359. PubMed ID: 36385619
[TBL] [Abstract][Full Text] [Related]
7. Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders.
Jordan JH; Jäger E; Sperr WR; Schwarzinger I; Födinger M; Fritsche-Polanz R; Ohler L; Geissler K; Valent P
Eur J Clin Invest; 2003 Jul; 33(7):611-8. PubMed ID: 12814399
[TBL] [Abstract][Full Text] [Related]
8. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.
Lübke J; Schwaab J; Christen D; Elberink HO; Span B; Niedoszytko M; Gorska A; Lange M; Gleixner KV; Hadzijusufovic E; Solomianyi O; Angelova-Fischer I; Zanotti R; Bonifacio M; Bonadonna P; Shoumariyeh K; von Bubnoff N; Müller S; Perkins C; Elena C; Malcovati L; Hagglund H; Mattsson M; Parente R; Varkonyi J; Fortina AB; Caroppo F; Zink A; Brockow K; Breynaert C; Bullens D; Yavuz AS; Doubek M; Sabato V; Schug T; Niederwieser D; Hartmann K; Triggiani M; Gotlib J; Hermine O; Arock M; Kluin-Nelemans HC; Panse J; Sperr WR; Valent P; Reiter A; Jawhar M
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):581-590.e5. PubMed ID: 36403897
[TBL] [Abstract][Full Text] [Related]
11. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
Sperr WR; Jordan JH; Fiegl M; Escribano L; Bellas C; Dirnhofer S; Semper H; Simonitsch-Klupp I; Horny HP; Valent P
Int Arch Allergy Immunol; 2002 Jun; 128(2):136-41. PubMed ID: 12065914
[TBL] [Abstract][Full Text] [Related]
12. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
Zanotti R; Bonifacio M; Lucchini G; Sperr WR; Scaffidi L; van Anrooij B; Oude Elberink HN; Rossignol J; Hermine O; Gorska A; Lange M; Hadzijusufovic E; Miething C; Müller S; Perkins C; Shomali W; Elena C; Illerhaus A; Jawhar M; Parente R; Caroppo F; Solomianyi O; Zink A; Mattsson M; Yavuz AS; Panse J; Varkonyi J; Doubek M; Sabato V; Breynaert C; Vucinic V; Schug T; Hägglund H; Wortmann F; Brockow K; Angelova-Fischer I; Belloni Fortina A; Triggiani M; Reiter A; Hartmann K; Malcovati L; Gotlib J; Shoumariyeh K; Niedoszytko M; Arock M; Kluin-Nelemans HC; Bonadonna P; Valent P
Leukemia; 2022 Feb; 36(2):516-524. PubMed ID: 34545185
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD34
Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
[TBL] [Abstract][Full Text] [Related]
14. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
[TBL] [Abstract][Full Text] [Related]
15. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis.
Sperr WR; Escribano L; Jordan JH; Schernthaner GH; Kundi M; Horny HP; Valent P
Leuk Res; 2001 Jul; 25(7):529-36. PubMed ID: 11377677
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
17. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking.
Hauswirth AW; Escribano L; Prados A; Nuñez R; Mirkina I; Kneidinger M; Florian S; Sonneck K; Vales A; Schernthaner GH; Sanchez-Muñoz L; Sperr WR; Bühring HJ; Orfao A; Valent P
Int J Immunopathol Pharmacol; 2008; 21(4):797-806. PubMed ID: 19144265
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
19. Determination of plasma heparin level improves identification of systemic mast cell activation disease.
Vysniauskaite M; Hertfelder HJ; Oldenburg J; Dreßen P; Brettner S; Homann J; Molderings GJ
PLoS One; 2015; 10(4):e0124912. PubMed ID: 25909362
[TBL] [Abstract][Full Text] [Related]
20. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
